GlobeNewswire by notified

Roche launches cobas 5800, a new molecular diagnostics system to expand access to testing and improve patient care

Share
  • Infectious diseases, such as those infections transmitted via respiratory, sexually and transplant, are becoming increasingly difficult to manage and represent an ever-growing medical need for millions of patients worldwide.
  • Access to accurate and reliable diagnostic tests help clinicians improve patient care, limit healthcare spending and contribute to protecting public health.
  • The cobas 5800 System is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes so clinicians can quickly determine the best treatment strategies for their patients.

Basel, 18 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. Testing is one of the first lines of defense to protect a patient’s general well-being and is vitally important in quickly guiding their treatment. The cobas 5800 System helps address challenges that laboratories are facing from an increase in patient testing, reimbursement complexities and the need for a more diverse testing menu while providing meaningful and timely results.  

“Diagnostics continue to revolutionise how providers care for patients, and it is essential, now more than ever, that the healthcare community has access to reliable and accurate testing solutions,” said Thomas Schinecker, CEO Roche Diagnostics. ”We are pleased that we can now offer a compact, fully-automated molecular system such as the cobas 5800 System. This new system helps to address the high demands on labs through greater efficiency, optimised workflows and cost savings, enabling them to deliver quality patient care.” 

The cobas 5800 system, the newest member of the Roche Molecular Work Area, is built upon the innovation of the cobas® 6800 and cobas® 8800 systems, making molecular testing accessible to more patients around the world.

Roche anticipates receiving U.S. Food and Drug Administration approval during Q3 2022.

About the cobas 5800 System
The cobas 5800 System is a real-time PCR molecular testing solution that provides excellent performance and value-added utility from a compact footprint. The cobas 5800 System delivers automation, consolidation, integration and standardisation – making it a scalable, cost-efficient solution for smaller labs seeking big lab performance, or for bigger labs seeking small lab agility.

The system is built to offer a fully automated workflow that encompasses sample supply, transfer and preparation, amplification and detection, result calculation and delivery to the laboratory information system (LIS). The single module enables a walkaway time of up to eight hours*, resulting in less hands-on time, which can lead to improved productivity, reduced possibility for errors and more predictable turnaround times.

The cobas 5800 System will offer the same menu as the cobas 6800 and 8800 Systems, including the cobas® SARS-CoV-2 test. The system offers an expanded on board capacity allowing labs to test multiple assays simultaneously and delivers up to 144 results in an eight-hour shift. This streamlined molecular testing system will allow most labs to consolidate greater than 90 percent** of their routine molecular tests onto a single platform. For more information please visit diagnostics.roche.com.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the thirteenth consecutive year, Roche has been recognised as one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

*Walkaway time is dependent on the number of tests performed and number of runs initiated (under continuous testing conditions >96 tests per shift, walkaway time may be between 4 - 8 hours).
**May vary based on assay availability in your country.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17
Sileia Urech
Phone: +41 79 935 81 48

Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
Karsten Kleine
Phone: +41 61 682 28 31

Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05

Roche Investor Relations

Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS2.12.2021 10:10:00 CET | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-12-02Loan194Coupon1.00 %ISIN-codeSE0012142206Maturity2024-09-18 Tendered volume, SEK mln400 +/- 200 Volume offered, SEK mln1,600 Volume bought, SEK mln600 Number of bids5 Number of accepted bids3 Average yield0.230 %Lowest accepted yield0.226 %Highest yield0.234 %% accepted at lowest yield 50.00 Auction date2021-12-02Loan1594Coupon2.00 %ISIN-codeSE0011062892Maturity2028-09-01 Tendered volume, SEK mln1,300 +/- 650 Volume offered, SEK mln2,600 Volume bought, SEK mln50 Number of bids5 Number of accepted bids1 Average yield0.857 %Lowest accepted yield0.857 %Highest yield0.857 %% accepted at lowest yield 100.00 Auction date2021-12-02Loan146Coupon0.50 %ISIN-codeSE0013381571Maturity2025-06-11 Tendered volume, SEK mln600 +/- 300 Volume offered, SEK mln1,700 Volume bought, SEK mln900 Number of bids3 Number of accepted bids2 Average yield0.395 %Lowest accepted yield0.395 %Highest yield0.395 %% accepted at lowest yield 81.82

Incap Corporation: Incap’s schedule for financial reporting in the year 20222.12.2021 08:30:00 CET | Press release

Incap Corporation: Incap’s schedule for financial reporting in the year 2022 Incap Corporation will publish the following financial reports in 2022: financial statements release for 2021 on Thursday, 24 February 2022 annual report for 2021 during week 13/2022 (week commencing on 28 March 2022) business review for January-March 2022 on Wednesday, 27 April 2022 half-year report for January-June 2022 on Thursday, 28 July 2022 business review for January-September 2022 on Thursday, 27 October 2022. The annual report includes the report of the Board of the Directors, the financial statements of the Group and the parent company as well as the auditor’s report for the financial period 1 January–31 December 2021. At the same time, the company will also publish the corporate responsibility report, the report on Corporate Governance as well as the report on remuneration. Incap’s Annual General Meeting is scheduled to be held on Friday, 29 April 2022 in Helsinki. A shareholder has the right to ha

Strategic Business Update - Acquisition of Precise-ITC and completion of major milestones for China Product Partnership2.12.2021 08:00:00 CET | Press release

LONDON and TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Alphawave IP (LN:AWE), a global leader in high-speed connectivity for the world’s technology infrastructure, is pleased to announce the acquisition of Precise-ITC and the completion of significant milestones for the China Product Partnership (“CPP”). Key highlights Alphawave IP has agreed to acquire Precise-ITC, Inc., an emerging leader in the Ethernet and Optical Transport Network (OTN) communications connectivity IP space. Alphawave IP has also completed all CPP implementation milestones and CPP, now incorporated as WiseWave Technology Co., Ltd (“WiseWave”), has been funded and will receive its first IP delivery from Alphawave IP in December 2021, as planned. WiseWave was founded as a Chinese semiconductor device company focused on the mainland Chinese market. In addition, Alphawave IP has completed the consolidation of its VeriSilicon reseller relationship with WiseWave to provide one interface to customers in China, in line with

Terranet Capital Markets Day on the 6th of December is around the corner2.12.2021 08:00:00 CET | Press release

On the 6th of December Terranet welcomes you to an exclusive day where you will be exposed to some of the avant garde brains in the Terranet ecosystem and the global automotive industry. At this event Terranet will reveal the latest progress and milestone achievements and showcase some insights behind the industry-collaborations. Please ensure you reserve your seat for the event in Stockholm here, only limited seats availiable: https://bit.ly/3mflryl Each presentation will be broadcasted and distributed live digitally. Sign up here: https://bit.ly/3B308UP Please find the updated schedule below: The schedule of the day (CET): 10:10 - 10.15 Ronja Koepke, Moderator 10:15 - 10.25 Par-Olof Johannesson, CEO Terranet 10:25 - 10:30 Ronja Koepke, Moderator 10:30 - 10.45 Jan Glevén, Head of Insight Mangold Fondkommission. 10:45 - 10.50 Ronja Koepke, Moderator 10:50 - 11:05 Panel discussion Jan Glevén, Head of Insight Mangold Fondkommission & Hampus Engellau, Handelsbanken Capital Markets 11.05 -

Systemairs rapport för det andra kvartalet presenteras den 9 december2.12.2021 08:00:00 CET | Pressemelding

Pressmeddelande 2 december 2021 Systemair ABs (NASDAQ OMX Stockholm: SYSR) delårsrapport Q2 för räkenskapsåret 2021/22 kommer att offentliggöras kl. 08:00 CET den 9 december 2021. En telefonkonferens arrangeras kl. 09:00 CET den 9 december 2021. Rapporten presenteras av Roland Kasper, CEO, samt Anders Ulff, CFO. För att delta i telefonkonferensen: Ring 0200-883 685 alt. internationellt +46 8 566 426 51 och uppge kod 50215855# minuter före start. Presentationen publiceras på group.systemair.com För ytterligare information kontakta: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, 739 30 Skinnskatteberg, 0222-440 00, www.systemair.com Systemair i korthet Systemair är ett ledande ventilationsföretag med verksamhet i 54 länder i Europa, Nordamerika, Sydamerika, Mellanöstern, Asien, Australien och Afrika. Bolaget omsatte 8,5 miljarder kronor räkenskapsåret 2020/21 och har cirka 6 400 anställda. Sedan grundandet av Systemair 1974 har bolaget uppvisat po

Systemair's Interim Report for the second quarter will be presented on December 92.12.2021 08:00:00 CET | Press release

Press Release, 2 December 2021 Systemair ABs (NASDAQ OMX Stockholm: SYSR) Interim Report Q2 for the financial year 2021/22 will be published at 08:00 CET on December 9, 2021. A telephone conference will be held at 09:00 CET on December 9, 2021. The report will be presented by Roland Kasper, CEO, and Anders Ulff, CFO. In order to participate in the telephone conference: Call 0200-883 685 alternative international call +46 8 566 426 51 and enter code 50215855# minutes before start. The presentation will be published on group.systemair.com For further information contact: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, SE-739 30 Skinnskatteberg, Sweden, +46 222 440 00, www.systemair.com Systemair in brief Systemair is a leading ventilation company with operations in 54 countries in Europe, North America, South America, the Middle East, Asia, Australia and Africa. The Company had sales of SEK 8.5 billion in the 2020/21 financial year and employs appr

Terranets kapitalmarknadsdag inträffar nu på måndag den 6 december 20212.12.2021 08:00:00 CET | Pressemelding

Den 6 december välkomnar Terranet dig till en exklusiv dag där du kommer att få lyssna till några av de högaktuella aktörerna i Terranets ekosystem samt innovatörer i den globala fordonsindustrin. Vid detta event kommer Terranet att presentera de senaste tekniska framstegen och delge strategier bakom enskilda branschsamarbeten. Evenemanget är både digitalt och fysiskt. För en fysisk biljett bokar du din plats till Stockholmsevenemanget här, ett begränsat antal platser finns tillgängliga: https://bit.ly/3mflryl Adress: Posthuset, Vasagatan 28, 111 20 Stockholm Sweden Varje presentation kommer även att sändas och distribueras live digitalt. Anmäl dig till det digitala eventet här: https://bit.ly/3B308UP Här hittar du det uppdaterade schemat (CET): 10:10 - 10.15 Ronja Koepke, Moderator 10:15 - 10.25 Pär-Olof Johannesson, CEO Terranet 10:25 - 10:30 Ronja Koepke, Moderator 10:30 - 10.45 Jan Glevén, Head of Insight Mangold Fondkommission. 10:45 - 10.50 Ronja Koepke, Moderator 10:50 - 11:05 P